Mai Mostafa Ahmed Mostafa Seleem

Taghreed A. Majrashi; Tarfah Al-Warhi; Wagdy M. Eldehna; Nada M. Mostafa

16/11/2023

https://www.sciencedirect.com/science/article/pii/S1756464623005005

Mai Mostafa Ahmed Mostafa Seleem

01/09/2023

https://www.eurchembull.com/uploads/paper/927edf1d31b6bc8a8a37a0ee726c6cba.pdf

Mai Mostafa Ahmed Mostafa Seleem

Amira A.Shaheen

20/02/2023

https://link.springer.com/article/10.1007/s11011-023-01182-x

Mai Mostafa Ahmed Mostafa Seleem

Nancy N. Shahin, Mohamed A. AbdelHafez, Tarek K. Motawai

06/02/2023

https://www.sciencedirect.com/science/article/pii/S0969996123000463

Mai Mostafa Ahmed Mostafa Seleem

18/05/2022

https://fjps.springeropen.com/articles/10.1186/s43094-022-00417-5

Mai Mostafa Ahmed Mostafa Seleem

Marwa Shabayek, Heba A Ewida

01/05/2021

Mai Mostafa Ahmed Mostafa Seleem

Samar H Ibrahim,Karim M El-Mehdawy , Maha M El-Sawalhi , Amira A Shaheen.

01/08/2020

Relapsing remitting multiple sclerosis (RRMS) is the most prevalent MS subtype. Years after disease onset, most of RRMS patients show transition into secondary progressive form (SPMS). Currently, no biomarkers are available for tracking disease progression. Here, we observed marked elevation of Rho-associated protein kinase 2 (ROCK2) along with significant downregulation of miRNAs 300 and 450b-5p expressions in the serum of 39 RRMS and 35 SPMS Egyptian patients compared to healthy controls. More pronounced alterations were found in SPMS versus RRMS patients. Our findings also suggest relations between elevated ROCK2 and reduced expression of both miRNAs with the degree of disability and disease progression. Notably, these biomarkers effectively discriminated RRMS from SPMS patients with miR-450b-5p showing the highest prognostic power.

Mai Mostafa Ahmed Mostafa Seleem

Ibrahim, S. H., K. M. El-Mehdawy, M. Seleem, M. M. El-Sawalhi and A. A. Shaheen.

01/08/2020

Mai Mostafa Ahmed Mostafa Seleem

01/01/2019

Background Dysregulation of miRNAs has been associated with many clinical conditions, including coronary artery disease (CAD). MiRNAs roles in patients with type 2 diabetes mellitus (T2D) with or without CAD, however, have not been clearly understood. Therefore we studied the expression of miRNAs 342 and 450 and the activity of the NADPH oxidase 4 (NOX‐4), and their association with anthropometric and biochemical parameters of hyperglycaemia and dyslipidaemia. Subjects and Methods Blood was collected from 200 outpatient subjects, divided into four groups of 50 individuals including control, T2D, CAD, and T2D with CAD. CAD was further divided based on CAD with angina, CAD clots, and CAD ischaemia to differentiate the primary cause of CAD. We measured the miRNAs 342 and 450 expression and NOX‐4 activity, in addition to routine parameters. Results The expression of miRNAs 342 and 450 and NOX‐4 activity was significantly different between groups. Furthermore, they presented significant correlations with routine parameters, providing evidence of a potentially beneficial role in stratifying the risk for CAD in patients with T2D. Conclusion The results of this study suggest that the expression of miRNAs 342 and 450 and NOX‐4 activity may help identify those individuals with T2D at high risk for developing CAD as well as the prognosis in those with established CAD.

Mai Mostafa Ahmed Mostafa Seleem

Ola S. Ali, Heba G. Abdelaziz, Dalia O. Makhlouf

01/12/2018

Breast cancer (BC) is the most common malignancy among women; supporting the need for identification of novel prognostic biomarkers, circulating microRNAs (miRNAs) could serve as such in various cancers. The aim of this study was to explore the association between miRNAs 182 and 375 with BC stages and its receptors, based on their expression using real time PCR. Materials and Methods Detailed medical history was taken and blood samples were withdrawn from 80 female subjects divided over the studied groups. Patients ranged in age from 24 to 80 years and were classified as follows: group I included 10 noncancerous postmenopausal control subjects; group II included 32 postmenopausal patients with BC; group III included 10 noncancerous premenopausal control subjects; group IV included 24 premenopausal patients with BC; and group V included 6 patients with benign breast tumors. Results miRNA 182 expression was significantly higher in group II, group IV, and group V (3.36 ± 0.14, 2.52 ± 0.34, and 4.93 ± 0.3,9 respectively); miRNA 375 expression was significantly higher in group II, group IV, and group V (4.41 ± 0.40, 3.12 ± 0.35, and 11.28 ± 2.37, respectively) (P < .05). Both miRNAs were significantly associated with each other and with receptors used for the prognosis of BC even after multiple regression analysis. Conclusion Accordingly, miRNAs 182 and 375 could be potential noninvasive markers used for the follow up of BC patients.